Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab, BMC Cancer

Background The link between immediate hypersensitivity reactions (HSR) following the first cetuximab infusion and the IgE sensitization against anti-galactose-α-1,3-galactose (α-Gal) is now well-established. An automated Fluoroenzyme-Immunoassay (FEIA) is available and may facilitate the screening of patients with anti-α-Gal IgE before treatment. Methods This study aimed to evaluate its performances as compared to a previously validated anti-cetuximab IgE ELISA, using 185 samples from two previously studied cohorts. Results Despite 21.1% of discrepancies between the two techniques, FEIA discriminated better positive patients and similarly negative ones with a ≥ 0.525 kUA/L threshold. Sensitivity was 87.5% for both tests, specificity was better for FEIA (96.3% vs ELISA: 82.1%). FEIA had a higher positive likelihood ratio (23.9 vs ELISA: 4.89) and a similar negative likelihood ratio (0.13 vs ELISA: 0.15). In our population, the risk of severe HSR following a positive test was higher with FEIA (56.7% vs ELISA: 19.6%) and similar following a negative test (0.7% vs ELISA: 0.8%). Conclusion Although the predictive value of the IgE screening before cetuximab infusion remains discussed, this automated commercial test can identify high-risk patients and is suitable for routine use in laboratories. It could help avoiding cetuximab-induced HSR by a systematic anti-α-Gal IgE screening before treatment.

IgE and mast cells in allergic disease

Description of the study population. HSR: Hypersensitivity reaction.

Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). - Abstract - Europe PMC

Allergen Exposure: When Timing Is Everything - ScienceDirect

Forest plot and SROC curve. Download Scientific Diagram

Anaphylaxis Induced by Biologics Current Treatment Options in Allergy

Prevalence of anti-cetuximab IgE. IgE levels were measured in serum

(PDF) Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test

Frontiers IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy

IJMS, Free Full-Text

PDF) Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection

PDF) Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. - Abstract - Europe PMC

Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test